MedTrace Logo

Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)

NCT05646199 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-05-10

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the effect of Semaglutide and metformin on weight loss in obese women with Polycystic Ovarian Syndrome (PCOS) over a 28-week treatment period.

The main question it aims to answer is:

• Which of the 2 drugs, metformin or Semaglutide causes more weight loss when used over a 28 week treatment period in obese women with PCOS?

Participants will be divided into 2 groups by chance. In the first group, participants will be asked to take metformin orally. In the second group, participants will take Semaglutide by injection under the skin weekly.

The maximum duration of participation for the patients in the trial is 32 weeks.

Researchers will compare the weight reduction, quality of life and individuals' wellbeing between the two groups.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

Metformin

Participants will receive metformin

DRUG

Semaglutide Injectable Product

Participants in this group will receive injectable Semaglutide

Sponsors & Collaborators

  • University of Hull

    lead OTHER

Principal Investigators

  • Thozhukat Sathyapalan, MD, FRCP · University of Hull

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-09-30
Completion
2025-12-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05646199 on ClinicalTrials.gov